Manufacturing mesenchymal stromal cells for phase I clinical trials.

Manufacturing mesenchymal stromal cells for phase I clinical trials.
复制标题

DOI:
10.1016/j.jcyt.2012.09.007
复制
发表时间:
2013-04
期刊:
影响因子:
4.5
通讯作者:
Horwitz EM
Horwitz EM
中科院分区:
医学3区
文献类型:
--
作者:
Hanley PJ;Mei Z;da Graca Cabreira-Hansen M;Klis M;Li W;Zhao Y;Durett AG;Zheng X;Wang Y;Gee AP;Horwitz EM

文献摘要

参考文献

被引文献

相似文献

间充质基质细胞(Mesenchymal stromal cells,MSCs)是一种多能祖细胞,能分化为脂肪细胞、成骨细胞和成软骨细胞,并分泌大量可溶性介质。这可能使MSC成为各种治疗应用的重要介质。它们正在积极评估免疫调节目的,如移植物抗宿主病(GvHD)和克罗恩病,以及再生应用,如中风和充血性心力衰竭。在这里,我们报告了我们的方法,产生临床级MSC连同建议,从我们的良好生产规范(GMP)设施的生产经验收集。
Mesenchymal stromal cells (MSCs) are multipotent progenitor cells capable of differentiating into adipocytes, osteoblasts, and chondroblasts as well as secreting a vast array of soluble mediators. This potentially makes MSCs important mediators of a variety of therapeutic applications. They are actively under evaluation for immunomodulatory purposes such as graft-versus host disease (GvHD) and Crohn’s disease, as well as regenerative applications such as stroke and congestive heart failure. Here we report our method of generating clinical-grade MSCs together with suggestions gathered from manufacturing experience in our Good Manufacturing Practices (GMP) facility.
DOI: 10.1155/2012/465259
发表时间: 2012
影响因子: 4.3
作者:
Fossett E;Khan WS
通讯作者: Khan WS
DOI: 10.1089/scd.2010.0589
发表时间: 2012-01-01
影响因子: 4
作者:
Vidal, Martin A.;Walker, Naomi J.;Borjesson, Dori L.
通讯作者: Borjesson, Dori L.
DOI: 10.1080/14653240600920782
发表时间: 2006-11-01
期刊: CYTOTHERAPY
影响因子: 4.5
作者:
Mueller, I.;Kordowich, S.;Dominici, M.
通讯作者: Dominici, M.
DOI: 10.1182/blood-2009-05-219907
发表时间: 2010-02-25
期刊: BLOOD
影响因子: 20.3
作者:
Tarte, Karin;Gaillard, Julien;Sensebe, Luc
通讯作者: Sensebe, Luc
DOI: 10.1089/scd.2009.0418
发表时间: 2010-11-01
影响因子: 4
作者:
Tu, Zhidan;Li, Qing;Lin, Feng
通讯作者: Lin, Feng